Search This Blog

Friday, December 20, 2019

NewLink Genetics up 33% on FDA nod for Merck Ebola vaccine

NewLink Genetics (NLNK +32.9%) is up on more than an 8x surge in volume in response to the FDA’s approval of Merck’s Ebola vaccine Ervebo.
The company out-licensed the rights to the vaccine, known as rVSV-ZEBOV at the time, to Merck in 2014.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)